EP MedSystems Begins Enrollment in ICE CHIP Intracardiac Ultrasound Clinical Trial

WEST BERLIN, N.J.--(BUSINESS WIRE)--May 3, 2005--EP MedSystems, Inc. (NASDAQ: EPMD - News), a market leader in electrophysiology products used in cardiac rhythm management, announced today initiation of the landmark ICE-CHIP(TM) (Intracardiac Echocardiograhpy guided Cardioversion to Help Interventional Procedures) multicenter clinical trial. This is EP MedSystems first clinical trial involving intracardiac ultrasound (ICE). The ICE CHIP trial, is a sequential Phase I and Phase II worldwide clinical trial, which compares the cardiac imaging capabilities of ICE during a cardiac catheterization procedure with standard transesophageal echocardiography (TEE), a separate standalone procedure in Phase 1. In Phase II immediate ICE guided cardioversion is compared to a conventional cardioversion strategy of greater than 3 weeks of warfarin therapy in patients with atrial fibrillation (AF). Both phases are designed to reduce need for additional procedures and prolonged delays in cardioversion therapy for AF patients. The ICE technique can be incorporated in standard cardiac catheterization and electrophysiologic procedures that are performed by cardiologists.

AF is a cardiac rhythm disorder in which causes the upper chamber of the heart (the atria) to quiver and pump blood inefficiently. AF is one of the most debilitating diseases in the world affecting over 5 million patients world wide and due to the inefficient pumping of the heart, blood can pool and clot in the heart. As a result, AF can often lead to stroke. The American Heart Association recommends aggressive treatment of this heart arrhythmia. Markers for stroke risk can be seen during TEE and ICE studies. ICE technology could potentially enable the physician to assess risk of stroke during atrial fibrillation which exists in up to 20% of the over one million patients who undergo cardiac catheterizations yearly.

Dr. Sanjeev Saksena, EP MedSystems' clinical advisor and ICE CHIP Study Chair, stated,"We believe this landmark trial will change the patterns of patient management in the field of atrial fibrillation. There is increasing evidence that non-pharmacologic therapies such as ablation will be increasingly used in patients with atrial flutter and fibrillation and intracardiac ultrasound allows the physician real-time beat-to-beat visualization inside a live human heart. This trial may eliminate a separate TEE procedure often performed before the therapeutic intervention is considered and, in contrast to TEE, can monitor patient safety and direct the intervention. This can potentially improve patient care, outcomes and reduce hospital stay. " The first patient has been enrolled in the ICE CHIP(TM) clinical trial at the University of Chicago by the site principal investigator, Dr. Bradley Knight.

About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMate® Electrophysiology Workstation with RPM(TM) Real-time Position Management(TM) navigation technology, the EP-4(TM) Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the ALERT® System and ALERT family of internal cardioversion catheters, and the ViewMate® intracardiac ultrasound catheter imaging. For more information, visit our Website at www.epmedsystems.com.

Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", "see opportunities" or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs, possible costs, fines or penalties that may be incurred in connection with government inquiries and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-KSB and quarterly reports filed on Form 10-Q and 10-QSB.

EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

For Further Information Contact:

EP MedSystems, Inc.
Matthew C. Hill
(856)753-8533

Investor Relations Firm:
MKR Group, LLC
Charles Messman, Todd Kehrli
(818)556-3700